Sana Biotechnology Showcases Successful In Vivo Gene Editing of Stem Cells in Nature Publication [Yahoo! Finance]
Sana Biotechnology, Inc. (SANA)
Company Research
Source: Yahoo! Finance
the publication of groundbreaking preclinical data in the journal Nature Biotechnology. The study, titled “In vivo gene editing of human hematopoietic stem and progenitor cells using envelope-engineered virus-like particles,” details the successful use of Sana's Fusogen platform to perform gene editing directly within the body. Using systemic delivery in murine models, the company showed that its virus-like particles/VLPs could precisely target and edit hematopoietic stem cells/HSCs inside the bone marrow, achieving stable results in long-term HSCs. The publication highlights the versatility of the Fusogen technology, which has now proven capable of delivering diverse payloads (including CRISPR gene-editing and base-editing machinery) to two distinct cell types: T cells and HSCs. A critical finding of the study was the platform's high specificity; the targeted particles successfully avoided off-target delivery to other organs, such as the liver (hepatocytes) or gonadal tissues. By
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- Sana Biotechnology (NASDAQ:SANA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SANA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen PlatformGlobeNewswire
- Sana Biotechnology (SANA): Assessing Valuation After Strong Year-to-Date Share Price Gains [Yahoo! Finance]Yahoo! Finance
- Sana Biotechnology to Present at December 2025 Investor ConferencesGlobeNewswire
- Sana Biotechnology (NASDAQ:SANA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SANA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
SANA
Earnings
- 8/11/25 - Beat
SANA
Sec Filings
- 12/16/25 - Form 4
- 12/5/25 - Form 4
- 11/14/25 - Form SCHEDULE
- SANA's page on the SEC website